In this episode, we discuss a different lens through which to look at entrepreneurship with John Bloomer. John has taken a journey from chemistry to agricultural seed technologies through advisory and board roles to his newly found vocation within the Church of England. John started his career at ICI and through a period of active mergers and acquisitions through the 1980s and 1990s, arrived at Syngenta, establishing the wheat and barley breeding business and migrating into an intrapreneur role with that organisation, before heading into independent consulting.
In this episode, we have the opportunity to reflect on the recent National Innovation Policy Forum in Canberra last month with my colleague, Dr Faisal Younus, who participated in the event. Thanks to Cooperative Research Australia, we also have been able to weave some excerpts from the panels into our discussions to try to offer some reflections and insights from the day’s events.
In this episode, I have the great pleasure of having our first omnipresent guest, Jim Lane, who is everywhere within the biobased economy with his leading daily publication The Digest. In the midst of driving the Bold Goals Initiative, catalysed by the US Inflation Reduction Act, and running the Advanced Bioeconomy Leadership Conference (ABLC), we catch up with Jim on current perspectives on the bioeconomy and a little soothsaying on what the next few years might look like.
I’m delighted to bring you a special podcast leading up to the 2023 National Innovation Policy Forum, presented by Cooperative Research Australia, to bring leaders from business, government, research – and boundary spanning organisations to focus on the future of the Australian innovation system.
I had the opportunity to have a pre-forum conversation with co-patrons Catherine Livingstone AO and David Thodey AO for their thoughts on the current innovation landscape, the role of policy, and the importance of a shared vision for Australia’s future.
In this episode, I have the great pleasure of having our first guest, Maurice Moloney, make a return appearance to revisit what’s been happening in protein over the past two years since our first discussion. Coming off the back of the International Rapeseed Congress (in September 2023), we explore the decline, or indeed collapse, of the alt-meat market and what the prospects are for it reaching its next growth phase.
In this episode, my guest is Shona Faber, Non-Executive Director of ARB Corporation, previously Managing Director CRC Industries, and General Manager of Specialty Gases & Chemicals at BOC. We talk about her experiences in bringing EDN, a novel fumigant chemical, licensed from CSIRO Entomology to market in her role at BOC. In discussing the journey that unfolded in this product coming to market, we touch on risk management and managing constant change as a new chemical is shepherded through various regulatory systems to market.
In this episode we talk with Elena Kelareva, CEO and Founder of GippsTech, about her experiences in establishing innovation systems in regional areas, and her reflections on the behavioural and cultural settings behind successful regional innovation ecosystems. We touch on the definition of tech transfer and tease out a distinction between innovation translating scientific outcomes and entrepreneurship, the latter being more broadly around the establishment of ventures to address new opportunities.
In this episode we had the chance to catch up with Cameron Hibbert, a long-standing colleague and friend who has been in global licensing roles at LyondellBassell Industries and Genomatica. We talk about when I first met Cameron at Montell and his journey to Germany through carrying responsibility for technology transfer at the Geelong polypropylene production plant. We explore his experiences moving from licensee to licensor in his role with LyondellBassell Industries taking responsibility for polyolefin licensing activities.
In this episode, we were pleased to have a wide-ranging discussion with Paul Wood. We talk about his start at CSIRO and the pathway to his breakthrough in TB tests for cattle in the Northern Territory, and how it opened a pathway into animal and human health research leadership. We discuss a few ‘sliding door’ moments with Paul around Qiagen, Cellestis, CSL and Pfizer, and how he ended up with the ‘keys to the lolly shop’ with Pfizer Animal Health (now Zoetis) in North America.